Colin Orford, PhD, is a veteran pharmaceutical executive with over 34 years of experience, including leadership roles at SmithKline Beecham, GSK, Novartis, Quintiles, Eisai, ICON, and Clinilabs. He previously served as SVP and Head of Drug Development Consulting Services at ICON plc., and Global Head of Neurosciences and General Medicine at Eisai.
With 22 years of global project leadership, Colin has advanced more than 20 assets from preclinical to late-stage development and contributed to five NDA submissions. His therapeutic expertise spans neuroscience—covering depression, anxiety, Alzheimer’s, sleep disorders, epilepsy, schizophrenia, and MS—with deep knowledge of both monoaminergic and non-monoaminergic mechanisms.
He has led strategic initiatives, global programs, and due diligence efforts, and brings strong regulatory experience across the US, EU, and Japan. Notable achievements include leading the Clozaril Japanese submission and contributing to the global success of Paroxetine.
